首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1299825

[月太]癌症治療藥的全球市場，用量，價格，銷售額，臨床試趨勢:2029年

Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029

出版日期: 2023年06月30日 | 出版商:

KuicK Research | 英文 600 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球[月太]癌症治療藥的市場規模，有超過150億美元的市場機會。

本報告提供全球[月太]癌症治療藥市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，各地區趨勢，及加入此市場的主要企業的競爭情形等資訊。

Firmagon (Degarelix)
Eligard (Leuprolide)
Lupron (Leuprolide Acetate)
Supprelin LA (Histrelin Acetate)
Gonax (Degarelix Acetate)
Trelstar (Triptorelin)
Decapeptyl SR (Treptorelin Acetate or Pamoate)
Velcade (Bortizomib)
Ninlaro (Ixazomib)
Kyprolis (Carfilzomib)
Istodax (Romidepsin)
Zoladex (Goserelin)
Cosmegen (Dactinomycin)
Somatuline Depot (Lanreotide)
Suprefact (Buserelin)
Sandostatin (Octreotide Acetate)
Bynfezia Pen (Octreotide)
Mepact (Mifamurtide)
Lutathera (Lutetium Lu 177 dotatate)
Netspot (Gallium Ga 68 dotatate)

第5章已上市的癌症[月太]藥的銷售額相關洞察(2019年～2023年)

Lupron
Kyprolis
Zoladex
Lutathera
Sandostatin
Somatuline
Decapeptyl SR
Velcade
Ninlaro

第6章全球[月太]癌症治療臨床試驗概要

各企業
各國
各適應症
各患者市場區隔
各代
各製劑

第7章全球[月太]癌症治療臨床試驗的洞察，各企業，各國，各適應症，[月太]各市場區隔

調查
前臨床
第一階段
第一/二階段
第二階段
第二/三階段
第三階段
預註冊
登記完畢

第8章市售癌症[月太]的臨床性洞察，各企業，各國，及各適應症

第9章全球[月太]癌症治療市場動態

第10章治療用[月太]的標的

信號傳達途徑
細胞週期的調節
細胞死的途徑
腫瘤抑制蛋白質
轉錄因子

第11章 [月太]醫藥品和傳統的癌症治療藥的比較

第12章癌症治療的[月太]的各種方法

第13章 [月太]治療方法的應用和癌症的檢測調查手法

大腸癌
肺癌
胰臟癌
胃癌
乳癌
前列腺癌

第14章新抗原疫苗:新的腫瘤免疫療法

第15章毒[月太]:癌症[月太]治療的新時代

第16章競爭情形

3B Pharmaceuticals
AsclepiX Therapeutics
Bicycle Therapeutics
Biohaven Labs
BrightPath Biotherapeutics
Bristol-Myers Squibb
Edinburgh Molecular Imaging
FogPharma
GE Healthcare
Gnubiotics Sciences
Harvard University
Heidelberg Pharma AG
IDP Pharma
Janux Therapeutics
Medikine
Modulation Therapeutics
Novartis
PeptiDream
Pharm-Sintez
Roche
Sanofi
Sapience Therapeutics
Second Genome
Viewpoint Molecular Targeting
Vigeo Therapeutics

簡介目錄圖表

“Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029” Report Highlights:

Global Peptide Drug Market Opportunity: > USD 15 Billion
Marketed Cancer Peptides Drugs Sales Insight 2019 - 2023
Marketed Cancer Peptides Drugs Dosage, Patent& Price Insight
Marketed Cancer Peptides Drugs Clinical & Commercial Insight: 25 Drugs
Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs
Global Peptide Cancer Drug Clinical Trials Insight By Company, Country Indication & Phase
Peptide Drug Development Proprietary Technologies By Company & Indication

Biologics have been an important class of drugs for several diseases including cancer. Till now, antibodies have dominated this domain of therapeutics but driven by new technological innovations, researchers have now shifted their new drug development approach towards peptides as preferred choice of anti-cancer agents. For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has been a new area of interest. Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.

The development of peptide based drugs and therapies have made great progress in the last decade owing to several pharmaceutical companies developing novel proprietary technologies for producing innovative peptide therapeutics. For instance, South Korea's Nanotechnology and Integrated Bioengineering Centre (NBICE), pharmaceutical company has developed its own novel peptide therapeutic discovery and delivery technology platform called TOPscovery. The company has also created a subsequent clinical pipeline using this novel technology platform which is based on target oriented peptide therapeutic discovery and has target tissue / cell penetrating peptide delivery platform to delivery protein or antibody or siRNA into the target tissue such as that of the cancer cells.

This peptide discovery platform TOPscovery is focused on resolving fibrosis in liver, lung and heart and additionally, the platform technology to target tissue penetrating peptide carrier (NPEP - TPP) can be applied to protein, antibody having intracellular targets, this increase the efficacy and decreases the side effects to non - target. The development of proprietary platforms and novel technologies has been an increasingly important factor that is boosting innovation the today's development of peptide based anti-cancer therapies.

Moreover, the increasing number of companies collaborating and investing in the field is also a signification factor driving the growth of peptide therapeutics. A major reason of this has been the development of novel technologies. With more pharmaceutical companies and biotechs advancing their portfolio with innovative products developed from novel platforms, more companies gain interest in field which could ultimately lead to more collaboration or investment, increasing the overall competitive landscape of the merging global market of anti - cancer peptide therapies.

The trend of collaboration not only extends the research and development capabilities for both the companies but it also allows for assessing the investigational peptide product candidates and likely have an impact on global peptide therapeutic market in terms of increasing the pipeline of cancer peptides, advancements in discovery and optimization of products and the possibility of investigational several different combinational strategies.

For instance, in first quarter of 2023, PeptiDream announced a collaborative arrangement with Ono Pharmaceuticals to discover and develop novel macrocyclic constrained peptide-based drugs directed against targets chosen by Ono. Under the agreement, PeptiDream will apply its proprietary PDPS (Peptide Discovery Platform System) technology to identify and enhance macrocyclic constrained peptide drug candidates, while Ono will develop and commercialize the resulting peptide-based drugs globally under an exclusive license. PeptiDream will be eligible to receive an undisclosed upfront payment in addition to funding to carry out research, as well as added payments based on research, development and commercialization milestones based on global net sales.

In addition, the portfolio of novel cancer peptides with distinct characteristics expands as a result of the development of novel technologies and platforms by various pharmaceutical companies. This will provide diverse market opportunities for each and every therapeutic peptide product candidate. Furthermore, rise in the cancer prevalence and increasing research of the therapeutic use of cancer peptides is likely to be the key factors responsible for the growth of the market. Moreover, the increasing demand for effective and novel therapies can be further anticipated to bring more opportunities and growth in the market. Apart from this, awareness among healthcare professionals and patients about the significant adverse events associated with conventional cancer treatments will also lead to greater adoption towards peptide based therapeutics in cancer treatment.

Our report provides a comprehensive analysis about the current available anti-cancer peptide drugs and therapies while also providing information about their sales insight, patent information and their targeting cancer indication. Additionally, this report also includes the overall market perspective of peptides in different countries and provides a descriptive view on upcoming opportunities that might become available.

1. Introduction to Peptide Therapeutics

1.1 Overview of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Significance of Peptides as Cancer Therapeutics

2. Global Cancer Peptide Therapeutics Market Insight

2.1 Current Market Scenario
2.2 Global Cancer Peptide Therapeutics Market Forecast

3. Global Peptide Cancer Therapeutics Market Trend By Region

3.1 Japan
3.2 South Korea
3.3 China
3.4 Australia
3.5 US
3.6 Europe

4. Marketed Cancer Peptides Drugs Insight - Availability, Cost, Dosage, Indication & Patent Insight

4.1 Firmagon (Degarelix)
4.2 Eligard (Leuprolide)
4.3 Lupron (Leuprolide Acetate)
4.4 Supprelin LA (Histrelin Acetate)
4.5 Gonax (Degarelix Acetate)
4.6 Trelstar (Triptorelin)
4.7 Decapeptyl SR (Treptorelin Acetate or Pamoate)
4.8 Velcade (Bortizomib)
4.9 Ninlaro (Ixazomib)
4.10 Kyprolis (Carfilzomib)
4.11 Istodax (Romidepsin)
4.12 Zoladex (Goserelin)
4.13 Cosmegen (Dactinomycin)
4.14 Somatuline Depot (Lanreotide)
4.15 Suprefact (Buserelin)
4.16 Sandostatin (Octreotide Acetate)
4.17 Bynfezia Pen (Octreotide)
4.18 Mepact (Mifamurtide)
4.19 Lutathera (Lutetium Lu 177 dotatate)
4.20 Netspot (Gallium Ga 68 dotatate)

5. Marketed Cancer Peptides Drugs Sales Insight (2019 -2023)

5.1 Lupron
5.2 Kyprolis
5.3 Zoladex
5.4 Lutathera
5.5 Sandostatin
5.6 Somatuline
5.7 Decapeptyl SR
5.8 Velcade
5.9 Ninlaro

6. Global Peptide Cancer Therapeutics Clinical Trials Overview

6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
6.6 By Drug Formulation

7. Global Peptide Cancer Therapeutics Clinical Trials Insight By Company, Country, Indication & Peptide Segment

7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
7.8 Preregistration
7.9 Registered

8. Marketed Cancer Peptides Clinical Insight by Company, Country & Indication

9. Global Peptide Cancer Therapy Market Dynamics

9.1 Favorable Market Parameters
9.2 Commercialization Challenges

10. Targets for Therapeutic Peptides

10.1 Signal Transduction Pathways
10.2 Cell Cycle Regulation
10.3 Cell Death Pathways
10.4 Tumor Suppressor Protein
10.5 Transcription Factors

11. Peptide Drugs v/s Conventional Cancer Therapeutics

11.1 Peptide v/s Chemotherapy
11.2 Peptide v/s Monoclonal Antibody
11.3 Peptide v/s Gene Therapy
11.4 Peptide v/s Immunotherapy

12. Different Approaches of Peptides in Cancer Therapeutics

12.1 Hormonal Peptides
12.2 Peptide as Radionuclide Drug Carrier
12.3 Peptide Vaccines
12.4 Peptides as Cytotoxic Drug Carrier
12.5 Anticancer Peptides
12.6 Other Anticancer Drugs Closely Related to Peptides

13. Application of Peptides Therapeutics & Detection Methodology by Cancer

13.1 Colorectal Cancer

13.1.1 Peptides in Treatment of Colorectal Cancer
13.1.2 Proprietary Technologies

13.2 Lung Cancer

13.2.1 Peptides in Treatment of Lung Cancer
13.2.2 Proprietary Technologies

13.3 Pancreatic Cancer

13.3.1 Peptide in Treatment of Pancreatic Cancer
13.3.2 Proprietary Technologies

13.4 Gastric Cancer
- 13.4.1 Peptides in Treatment of Gastric Cancer
- 13.4.2 Proprietary Technologies
13.5 Breast Cancer
- 13.5.1 Peptides in Treatment of Breast Cancer
- 13.5.2 Proprietary Technologies
13.6 Prostate Cancer
- 13.6.1 Peptides in Treatment of Prostate Cancer
- 13.6.2 Proprietary Technologies

14. Neoantigen Vaccine: An Emerging Tumor Immunotherapy

14.1 Personalized Neoantigen Based Vaccine in Cancer
14.2 Ongoing Clinical Advancements

15. Venom Peptides: New Era for Cancer Peptide Therapy

15.1 Relevance of Venom Based Peptide Therapeutics
15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

16. Competitive Landscape

16.1 3B Pharmaceuticals
16.2 AsclepiX Therapeutics
16.3 Bicycle Therapeutics
16.4 Biohaven Labs
16.5 BrightPath Biotherapeutics
16.6 Bristol-Myers Squibb
16.7 Edinburgh Molecular Imaging
16.8 FogPharma
16.9 GE Healthcare
16.10 Gnubiotics Sciences
16.11 Harvard University
16.12 Heidelberg Pharma AG
16.13 IDP Pharma
16.14 Janux Therapeutics
16.15 Medikine
16.16 Modulation Therapeutics
16.17 Novartis
16.18 PeptiDream
16.19 Pharm-Sintez
16.20 Roche
16.21 Sanofi
16.22 Sapience Therapeutics
16.23 Second Genome
16.24 Viewpoint Molecular Targeting
16.25 Vigeo Therapeutics

簡介目錄圖表

List of Figures

Figure 1-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery
Figure 1-2: Classification of Anticancer Peptides
Figure 1-3: Significance of Peptides as Cancer Therapeutics
Figure 1-4: US - Per Unit Cost of Cancer Drugs (US$)
Figure 1-5: Role of Peptides in Cancer Immunotherapy
Figure 2-1: Factors Driving The Global Market Of Cancer Peptides
Figure 2-2: Countries Leading In Research & Development Of Cancer Peptides
Figure 2-3: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
Figure 2-4: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
Figure 4-1: Firmagon - Patent Issue & Expiration Years
Figure 4-2: Firmagon - Price per Unit for Supply of 80 mg & 120 mg Powder for Subcutaneous Injection (US$), June'2023
Figure 4-3: Firmagon - Starting & Maintenance Dosage (mg)
Figure 4-4: Firmagon - Treatment Costs of Initial Cycle and Maintenance Cycle (US$), June'2023
Figure 4-5: Eligard - Cost of Different doses of Extended-Release Subcutaneous Powder for Injection (US$), June'2023
Figure 4-6: Eligard - Recommended Dosage for Prostate Cancer on Monthly Basis (mg)
Figure 4-7: Eligard - Annual Treatment cost of Prostate Cancer using Different available Doses (US$), June'2023
Figure 4-8: Lupron - Patent Issue & Expiration Year for Sustained Release Preparation
Figure 4-9: Lupron - Price for 7.5 mg, 22.5 mg, 30 mg & 40 mg Depot (US$), June'2023
Figure 4-10: Lupron - Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US$), June'2023
Figure 4-11: Lupron - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 4-12: Lupron - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), June'2023
Figure 4-13: Histrelin - FDA Approval Years by Brand Name
Figure 4-14: Supprelin LA - Patent Approval & Expiration Years
Figure 4-15: Histrelin - Price for Single 50mg Supprelin LA Implant (US$), June'2023
Figure 4-16: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), June'2023
Figure 4-17: Gonax - Starting & Maintenance Dosage (mg)
Figure 4-18: Trelstar - Patent Issue & Expiration Year
Figure 4-19: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), June'2023
Figure 4-20: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg)
Figure 4-21: Trelstar - Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), June'2023
Figure 4-22: Decapeptyl SR - Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US$), June'2023
Figure 4-23: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 4-24: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), June'2023
Figure 4-25: Velcade - Price for a Supply of 3.5 mg Powder for Injection (US$), June'2023
Figure 4-26: Bortizomib - Price for a Supply of 1mg, 2.5mg & 3.5mg Powder for Injection (US$), June'2023
Figure 4-27: Bortizomib - Price for a Supply of 3.5mg Powder for Intravenous Injection (US$), June'2023
Figure 4-28: Bortizomib - Price for a Supply of 1.4 mL Powder for Intravenous Solution (US$), June'2023
Figure 4-29: Ninlaro - Patent Issue & Expiration Years
Figure 4-30: Ninlaro - Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), June'2023
Figure 4-31: Ninlaro - Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week)
Figure 4-32: Kyprolis - Issue & Expiration Years of Patents Assigned to Proteolix Inc
Figure 4-33: Kyprolis - Issue & Expiration Years of Patent Assigned to Cydex Pharmaceutical
Figure 4-34: Kyprolis - Issue & Expiration Years of Patents Assigned to Onyx Therapeutics
Figure 4-35: Kyprolis - Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US$), June'2023
Figure 4-36: Kyprolis - Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m2/week)
Figure 4-37: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week)
Figure 4-38: Romidepsin - FDA Approval Year by Indication
Figure 4-39: Romidepsin - Price for a Supply of 10mg Branded & Generic Intravenous Powder (US$), June'2023
Figure 4-40: Romidepsin- Price for 5.5ml Supply & Price per ml of 5mg/ml Intravenous Solution (US$), June'2023
Figure 4-41: Romidepsin - Monthly & Yearly Cost Of Treatment (US$), June'2023
Figure 4-42: Zoladex - Cost of 3.6 mg & 10.8 mg Implant (US$), June'2023
Figure 4-43: Zoladex - Recommended Dose for Prostate cancer Management on Monthly Basis (mg)
Figure 4-44: Zoladex - Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), June'2023
Figure 4-45: Dactinomycin - Price for Generic & Branded 0.5 mg Powder for Injection (US$), June'2023
Figure 4-46: Cosmegen - Annual Cost of Wilms Tumor Treatment (US$), June'2023
Figure 4-47: Somatuline Depot - Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US$), June'2023
Figure 4-48: Somatuline Depot - Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), June'2023
Figure 4-49: Somatuline Depot - Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), June'2023
Figure 4-50: Lanreotide - Price of 120mg/0.5ml Supply & Price per unit of Generic Lanreotide Subcutaneous Solution (US$), June'2023
Figure 4-51: Somatuline Depot - Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), June'2023
Figure 4-52: Suprefact - Price of 6.3mg & 9.45mg Depot (US$), June'2023
Figure 4-53: Suprefact - Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US$), June'2023
Figure 4-54: Suprefact Injection - Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day)
Figure 4-55: Suprefact Depot - Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 4-56: Suprefact Depot - Annual Prostate Cancer Treatment Cost (US$), June'2023
Figure 4-57: Sandostatin - Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), June'2023
Figure 4-58: Sandostatin - Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), June'2023
Figure 4-59: Sandostatin - Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), June'2023
Figure 4-60: Sandostatin LAR - Price for Various Supplies of Intramuscular Powder for Injection (US$), June'2023
Figure 4-61: Octreotide - Price for 50 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
Figure 4-62: Octreotide - Price for 100 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
Figure 4-63: Octreotide - Price for 200 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
Figure 4-64: Octreotide - Price for 500 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
Figure 4-65: Octreotide - Price for 1000 mcg/mL Vials of Generic Octreotide Injectable Solution (US$), June'2023
Figure 4-66: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg)
Figure 4-67: Bynfezia Pen - Patent Issue & Expiration Year
Figure 4-68: Bynfezia Pen - Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US$), June'2023
Figure 4-69: Bynfezia Pen - Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
Figure 4-70: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
Figure 4-71: Germany - Cost of Single Dose & Full Treatment (EUR/US$), June'2023
Figure 4-72: Lutathera - Patent Issue & Expiration Years
Figure 4-73: Lutathera - RDP & ODE Regional Expiry Years
Figure 5-1: Global - Lupron Annual Sales (US$ Million), 2019-2021
Figure 5-2: US - Lupron Annual Sales (US$ Million), 2019-2021
Figure 5-3: ROW - Lupron Annual Sales (US$ Million), 2019-2021
Figure 5-4: Kyprolis - Annual Sales Value (US$ Million), 2018-2023
Figure 5-5: Kyprolis - Annual Sales by Region (%), Q1'2023
Figure 5-6: Global - Kyprolis Quarterly Sales Value (US$ Million), 2022
Figure 5-7: US - Kyprolis Quarterly Sales Value (US$ Million), 2022
Figure 5-8: ROW - Kyprolis Quarterly Sales Value (US$ Million), 2022
Figure 5-9: Global - Zoladex Annual Sales (US$ Million), 2019-2023
Figure 5-10: Regional - Zoladex Annual Sales (US$ Million), 2023
Figure 5-11: Regional - Zoladex Annual Sales (%), 2023
Figure 5-12: Global - Zoladex Quarterly Sales (US$ Million), 2022
Figure 5-13: Regional - Zoladex Annual Sales (US$ Million), 2022
Figure 5-14: Regional - Zoladex Annual Sales (%), 2022
Figure 5-15: US - Zoladex Annual Sales (US$ Million), 2019-2023
Figure 5-16: EU - Zoladex Annual Sales (US$ Million), 2019-2023
Figure 5-17: EM - Zoladex Annual Sales (US$ Million), 2019-2023
Figure 5-18: ROW - Zoladex Annual Sales (US$ Million), 2019-2023
Figure 5-19: Global - Lutathera Annual Sales (US$ Million), 2019-2023
Figure 5-20: Global - Lutathera Quarterly Sales (US$ Million), 2022
Figure 5-21: Global - Sandostatin Annual Sales (US$ Million), 2019-2023
Figure 5-22: Global - Sandostatin Quarterly Sales (US$ Million), 2022
Figure 5-23: Global - Somatuline Annual Sales (US$ Million), 2019-2023
Figure 5-24: Global - Somatuline Quarterly Sales (US$ Million), 2022
Figure 5-25: Global - Decapeptyl Annual Sales (US$ Million), 2019-2023*
Figure 5-26: Global - Decapeptyl Quarterly Sales (US$ Million), 2022
Figure 5-27: Global - Velcade Sales Value (US$ Million), 2019-2023
Figure 5-28: Regional - Velcade Sales Value (US$ Million), 2022
Figure 5-29: Regional - Velcade Sales Value (%), 2022
Figure 5-30: Global - Velcade Quarterly Sales Value (US$ Million), 2022
Figure 5-31: Ninlaro - Annual Sales Value (US$ Million), 2019-2023
Figure 5-32: Ninlaro - Annual Sales Value (US$ Million), 2022
Figure 5-33: Ninlaro - Annual Sales by Region (%), Q1'2023
Figure 5-34: Ninlaro - Annual Sales Value (US$ Million), 2022
Figure 5-35: Ninlaro - Annual Sales by Region (%), 2022
Figure 6-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
Figure 6-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2023
Figure 6-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2023
Figure 6-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of 2023
Figure 6-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2023
Figure 6-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2023
Figure 9-1: Favorable Market Factors for Cancer Peptide Development
Figure 9-2: Factors Challenging the Commercialization of Cancer Peptides
Figure 10-1: Therapeutic Peptides Based on Their Biological Targets
Figure 10-2: MAPK Signaling Pathways
Figure 10-3: Cell Cycle in Eukaryotic
Figure 10-4: Cell Death Pathways
Figure 10-5: Features of Bcl-2 Family Proteins
Figure 11-1: Limitations of Monoclonal Antibody
Figure 11-2: Monoclonal Antibodies & Peptide Therapeutics - Cost of Production per gram (US$)
Figure 11-3: Pre-Requisite for Gene Therapy
Figure 11-4: Limitations of Gene Therapy
Figure 11-5: Drawbacks of Immunotherapy
Figure 12-1: Different Approaches of Peptide in Cancer Management
Figure 12-2: Mode of Action - LHRH Agonist & LHRH Antagonist
Figure 12-3: Effects of Somatostatin Analogs
Figure 12-4: Peptide Receptor Radionuclide Therapy
Figure 12-5: Mechanism of Peptide Vaccines
Figure 13-1: EO2040 - Study Initiation & Expected Completion Year, June'2023
Figure 13-2: EO4010 - Study Initiation & Competition Year, June'2023
Figure 13-3: ELI-002 - Study Initiation & Competition Year, June'2023
Figure 13-4: CBX-12 - Study Initiation & Completion Year'2023
Figure 13-5: Enterome - OncoMimics Platform
Figure 13-6: Elicio Therapeutics - The AMP Platform
Figure 13-7: Alphalex - Selective Targeting of Tumor Cells
Figure 13-8: Treos Bio - PolyPEPI Approach
Figure 13-9: UCPVax - Study Initiation & Expected Completion Year, June'2023
Figure 13-10: GRN-1201 - Study Initiation & Competition Year, June'2023
Figure 13-11: PeptiCRAd-1 - Study Initiation & Completion Year, June'2023
Figure 13-12: Owlstone Medical - EVOC Probes for Targeted Assessment of Biological Pathways
Figure 13-13: Bicycle Therapeutics - Simple Bicycles
Figure 13-14: Bicycle Therapeutics - Tandems
Figure 13-15: Bicycle Therapeutics - Higher Order Bicycles
Figure 13-16: Bicycle Therapeutics - Bicycle Toxin Conjugate
Figure 13-17: PeptiCRAd - Immunology
Figure 13-18: T-Win Vaccines - Mechanism of Action
Figure 13-19: MB1707 - Study Initiation & Completion Year, June'2023
Figure 13-20: BT5528 - Study Initiation & Completion Year
Figure 13-21: IMU-131 - Study Initiation & Completion Year
Figure 13-22: OTSGC-A24 - Study Initiation & Completion Year
Figure 13-23: Bicycle Therapeutics - Bicycle Toxin Conjugate
Figure 13-24: HER-Vaxx - Active Immunization Mechanism of Action
Figure 13-25: Stress-Induced Post-Translational Modifications Cell Surface Peptides
Figure 13-26: Moditope - Mechanism of Action
Figure 14-1: Benefits of Neoantigens
Figure 14-2: Steps of Producing Neoantigen Vaccine
Figure 14-3: Neoantigen Vaccine - Mode of Action
Figure 15-1: Advantages of Venom Peptides